美国的 Amgen 公司以高达 840 万美元的价格收购英国生物科技公司 Dark Blue, Amgen buys UK biotech Dark Blue for up to $840M to gain a promising leukemia drug in development.

安进以最高8.4亿美元的全现金收购了总部位于英国的Dark Blue Therapeutics，扩展其肿瘤学产品线，推出DBT 3757，这是一种针对侵袭性急性骨髓系和淋巴母细胞白血病中MLLT1和MLLT3蛋白的临床前药物。 Amgen has acquired UK-based Dark Blue Therapeutics for up to $840 million in an all-cash deal, expanding its oncology pipeline with DBT 3757, a preclinical drug targeting MLLT1 and MLLT3 proteins in aggressive acute myeloid and lymphoblastic leukemias. 该疗法由牛津大学研究开发,并得到牛津科学企业、布里斯托尔·迈尔斯·斯奎布和埃沃特克的支持,利用有针对性的蛋白质退化来阻止癌症的生长。 The therapy, developed from Oxford University research and backed by Oxford Science Enterprises, Bristol Myers Squibb, and Evotec, uses targeted protein degradation to disrupt cancer growth. 安根计划整合暗蓝团队与科技, 以加速发展, 解决血液癌未得到满足的需要。 Amgen plans to integrate Dark Blue’s team and technology to accelerate development, aiming to address unmet needs in blood cancers. 收购反映了行业日益重视蛋白质退化治疗。 The acquisition reflects rising industry focus on protein degradation therapies.